(12) **Translation of European patent specification**

(11) **NO/EP 3377483 B1**

(19) NO

NORWAY

(51) Int Cl.

C07D 403/12 (2006.01) ***A61P 35/00 (2006.01)***
A61K 31/506 (2006.01) ***C07D 403/14 (2006.01)***
A61P 9/00 (2006.01) ***C07D 409/14 (2006.01)***
A61P 11/00 (2006.01) ***C07D 413/14 (2006.01)***
A61P 15/00 (2006.01) ***C07D 417/14 (2006.01)***
A61P 25/00 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2022.01.31
(80)	Date of The European Patent Office Publication of the Granted Patent	2021.09.01
(86)	European Application Nr.	16797577.0
(86)	European Filing Date	2016.11.17
(87)	The European Application's Publication Date	2018.09.26
(30)	Priority	2015.11.20, WO, PCT/EP15/077269
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Validation States:	MA
(73)	Proprietor	Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123 Allschwil, Sveits
(72)	Inventor	FRETZ, Heinz, Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91, 4123 Allschwil, Sveits LYOTHIER, Isabelle, Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91, 4123 Allschwil, Sveits POTHIER, Julien, Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91, 4123 Allschwil, Sveits RICHARD-BILDSTEIN, Sylvia, Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91, 4123 Allschwil, Sveits SIFFERLEN, Thierry, Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91, 4123 Allschwil, Sveits WYDER PETERS, Lorenza, Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91, 4123 Allschwil, Sveits POZZI, Davide, Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91, 4123 Allschwil, Sveits CORMINBOEUF, Olivier, Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91, 4123 Allschwil, Sveits
(74)	Agent or Attorney	PLOUGMANN VINGTOFT, Postboks 1003 Sentrum, 0104 OSLO, Norge

(54) Title **N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS**

(56) References Cited: EP-A1- 2 014 657, EP-A1- 2 711 364

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/

Patentkrav

1. Forbindelse av formel (I)



Formel (I)

hvori

$(R^1)_n$ representerer en, to eller tre valgfrie substituenter på indolringen, hvori substituentene er uavhengig valgt fra (C_{1-3})alkyl, (C_{1-3})alkoksy, halogen, (C_{1-3})fluoralkyl, (C_{1-3})fluoralkoksy eller cyano; eller to **R^1** sammen danner en gruppe -O-CH_2-O-, og den gjenværende **R^1,** hvis til stede, representerer halogen;
R^2 representerer (C_{1-4})alkyl, halogen eller cyano;
R^3 representerer hydrogen, metyl eller trifluormetyl;
R^{4a} og **R^{4b}** uavhengig representerer hydrogen, metyl eller **R^{4a}** og **R^{4b}** sammen med karbonatomet som de er festet til representerer en sykloprop-1,1-diylgruppe;
R^{5a} og **R^{5b}** uavhengig representerer hydrogen, metyl, eller **R^{5a}** og **R^{5b}** sammen med karbonatomet som de er festet til representerer en sykloprop-1,1-diylgruppe;
Ar^1 representerer

- fenyl, eller 5- eller 6-leddet heteroaryl; hvori fenylet eller det 5- eller 6-leddede heteroarylet uavhengig er mono-, di- eller tri-substituert, hvori substituentene er uavhengig valgt fra

- (C_{1-6})alkyl;

- (C_{1-4})alkoksy;

- (C_{1-3})fluoralkyl, hvori (C_{1-3})fluoralkylet eventuelt er substituert med hydroksy;

- (C_{1-3})fluoralkoksy;

• halogen;

• cyano;

• (C_{3-6})sykloalkyl, hvori (C_{3-6})sykloalkylet er usubstituert eller mono-substituert med amino;

• (C_{4-6})sykloalkyl som inneholder et ringoksygenatom, hvori (C_{4-6})sykloalkylet som inneholder et ringoksygenatom er usubstituert eller mono-substituert med fluor, hydroksy eller metoksy;

• (C_{3-6})sykloalkyl-oksy;

• hydroksy;

• nitro;

• -$B(OH)_2$;

• 2,2,2-trifluor-1,1-dihydroksy-etyl;

• -$\mathbf{X^1}$-CO-$\mathbf{R^{O1}}$, hvori

▪ $\mathbf{X^1}$ representerer en direktebinding, (C_{1-3})alkylen, -O-(C_{1-3})alkylen-*, -NH-(C_{1-3})alkylen-*, -S-CH_2-*, -CF_2-, -CH=CH-, -C=C-, -NH-CO-*, -CO- eller (C_{3-5})sykloalkylen; hvori asteriskene indikerer bindingen som er bundet til -CO-$\mathbf{R^{O1}}$-gruppen; og

▪ $\mathbf{R^{O1}}$ representerer

• -OH;

• -O-(C_{1-4})alkyl;

• -NH-SO_2-$\mathbf{R^{S3}}$ hvori $\mathbf{R^{S3}}$ representerer (C_{1-4})alkyl, (C_{3-6})sykloalkyl hvori (C_{3-6})sykloalkylet eventuelt inneholder et ringoksygenatom, (C_{3-6})sykloalkyl-(C_{1-3})alkylen hvori (C_{3-6})sykloalkylet eventuelt inneholder et ringoksygenatom, (C_{1-3})fluoralkyl, fenyl eller -NH_2;

• -O-fenyl;

• -O-CH_2-CO-$\mathbf{R^{O4}}$, hvori $\mathbf{R^{O4}}$ representerer hydroksy, eller (C_{1-4})alkoksy eller -N[(C_{1-4})alkyl]$_2$:

• -O-CH_2-O-CO-$\mathbf{R^{O5}}$, hvori $\mathbf{R^{O5}}$ representerer (C_{1-4})alkyl eller (C_{1-4})alkoksy;

• -O-CH_2-CH_2-N[(C_{1-4})alkyl]$_2$; eller

• (5-metyl-2-okso-[1,3]dioksol-4-yl)-metyloksy-;

• -CO-CH_2-CN;

• -CO-CH_2-OH;

• -CO-H;

•



•



• 2-hydroksy-3,4-diokso-syklobut-1-enyl;

• hydroksy-(C_{1-4})alkyl;

• dihydroksy-(C_{2-4})alkyl;

• hydroksy-(C_{2-4})alkoksy;

• (C_{1-4})alkoksy-(C_{2-4})alkoksy;

• -(CH_2)$_m$-N$\mathbf{R^{N1}}$$\mathbf{R^{N2}}$, hvori m representerer heltallet 0 eller 1; og hvori

▪ $\mathbf{R^{N1}}$ og $\mathbf{R^{N2}}$ uavhengig representerer hydrogen, (C_{1-4})alkyl, (C_{1-4})alkoksy-(C_{2-4})alkyl, (C_{3-6})sykloalkyl, (C_{2-3})fluoralkyl, eller -SO_2-(C_{1-4})alkyl;

▪ eller $\mathbf{R^{N1}}$ uavhengig representerer hydrogen eller (C_{1-4})alkyl, og $\mathbf{R^{N2}}$ uavhengig representerer -CO-H, -CO-(C_{1-3})alkyl, -CO-(C_{1-3})alkylen-OH eller -CO-O-(C_{1-3})alkyl;

▪ eller $\mathbf{R^{N1}}$ og $\mathbf{R^{N2}}$ sammen med nitrogenet de er festet til danner en 4-, 5- eller 6-leddet mettet ring som eventuelt inneholder ett ringoksygen- eller ringsvovelatom, hvori ringen er usubstituert, eller mono-substituert med okso på et ringkarbonatom, eller di-substituert med okso på et ringsvovelatom;

• -CO-N$\mathbf{R^{N3}R^{N4}}$ hvori $\mathbf{R^{N3}}$ og $\mathbf{R^{N4}}$ uavhengig representerer hydrogen, (C_{1-4})alkyl, hydroksy-(C_{2-4})alkyl, (C_{1-3})alkoksy-(C_{2-4})alkyl, dimetylamino-(C_{2-4})alkyl, (C_{1-4})alkoksy, hydroksy-(C_{2-4})alkoksy, benzyloksy eller hydroksy;

• -NH-CO-N$\mathbf{R^{N5}R^{N6}}$ hvori $\mathbf{R^{N5}}$ og $\mathbf{R^{N6}}$ uavhengig representerer hydrogen eller (C_{1-4})alkyl;

• -SO_2-$\mathbf{R^{S1}}$ hvori $\mathbf{R^{S1}}$ representerer hydroksy, (C_{1-4})alkyl eller -N$\mathbf{R^{N7}R^{N8}}$ hvori $\mathbf{R^{N7}}$ og $\mathbf{R^{N8}}$ uavhengig representerer hydrogen eller (C_{1-3})alkyl:

• -S-$\mathbf{R^{S2}}$ hvori $\mathbf{R^{S2}}$ representerer (C_{1-4})alkyl, (C_{3-6})sykloalkyl eller 2-fluor-vinyl;

• 5-okso-4,5-dihydro-[1,2,4]oksadiazol-3-yl, eller 3-okso-2,3-dihydro-[1,2,4]oksadiazol-5-yl;

• fenyl-oksy, hvori fenylet eventuelt er mono-substituert med halogen;

• benzooksazol-2-yl; eller

• -(CH_2)$_\mathbf{p}$**-HET,** hvori p representerer heltallet 0 eller 1; og hvori HET representerer et 5- eller 6-leddet heteroaryl, hvori det 5- eller 6-leddede heteroarylet er usubstituert, eller mono- eller di-substituert, hvori substituentene er uavhengig valgt fra (C_{1-4})alkyl, (C_{1-4})alkoksy, -COOH, hydroksy, fluor, 2-amino-2-okso-etyl, 2-karboksy-etyl, (C_{3-5})sykloalkyl eller -N$\mathbf{R^{N9}R^{N10}}$ hvori $\mathbf{R^{N9}}$ og $\mathbf{R^{N10}}$ uavhengig representerer hydrogen eller (C_{1-3})alkyl:

• eller **Ar^{1}** representerer 8- til 10-leddet bisyklisk heteroaryl; hvori det 8- til 10-leddede bisykliske heteroarylet uavhengig er usubstituert, mono-, di- eller tri-substituert, hvori substituentene er uavhengig valgt fra (C_{1-4})alkyl; (C_{1-4})alkoksy; (C_{1-3})fluoralkyl; (C_{1-3})fluoralkoksy; halogen; cyano; hydroksy, eller -(C_{0-3})alkylen-COO**R^{O2}** hvori **R^{O2}** representerer hydrogen eller (C_{1-4})alkyl;

• eller **Ar^{1}** representerer 8- til 10-leddet delvis aromatisk fusert bisyklisk heterosyklyl omfattende ett til fire heteroatomer uavhengig valgt fra nitrogen, oksygen og svovel; hvori det 8- til 10-leddede heterosyklylet er bundet til resten av molekylet ved den aromatiske ringdelen; hvori det 8- til 10-leddede heterosyklylet uavhengig er usubstituert, mono- eller di-substituert, hvori substituentene er uavhengig valgt fra okso, (C_{1-6})alkyl og -(C_{0-3})alkylen-COO**R^{O3}** hvori **R^{O3}** representerer hydrogen eller (C_{1-3})alkyl:

eller et farmasøytisk akseptabelt salt derav.

2. Forbindelse ifølge krav 1; hvori **R^{3}** representerer hydrogen;
eller et farmasøytisk akseptabelt salt derav.

3. Forbindelse ifølge kravene 1 eller 2; hvori

• **R^{4a}** og **R^{4b}** begge representerer hydrogen; og

• **R^{5a}** og **R^{5b}** begge representerer hydrogen;

eller et farmasøytisk akseptabelt salt derav.

4. Forbindelse ifølge et hvilket som helst av kravene 1 til 3, hvori **Ar^{1}** representerer

• fenyl, eller 5- eller 6-leddet heteroaryl; hvori fenylet eller det 5- eller 6-leddede heteroarylet uavhengig er mono-, di- eller tri-substituert;
hvori én av substituentene er valgt fra

• (C_{1-4})alkoksy;

• (C_{1-3})fluoralkyl, hvori (C_{1-3})fluoralkylet er usubstituert eller mono-substituert med hydroksy;

• (C_{3-6})sykloalkyl, hvori (C_{3-6})sykloalkylet er usubstituert eller mono-substituert med amino;

• (C_{4-6})sykloalkyl som inneholder et ringoksygenatom, hvori (C_{4-6})sykloalkylet som inneholder et ringoksygenatom er usubstituert eller mono-substituert med fluor, hydroksy eller metoksy;

• hydroksy;

• -$B(OH)_2$;

• 2,2,2-trifluor-1,1-dihydroksy-etyl;

• -$\mathbf{X^1}$-CO-$\mathbf{R^{O1}}$, hvori

▪ $\mathbf{X^1}$ representerer en direktebinding, (C_{1-3})alkylen, -O-(C_{1-3})alkylen-*, -NH-(C_{1-3})alkylen-*, -S-CH_2-*, -CF_2-, -CH=CH-, -C=C-, -NH-CO-*, -CO- eller (C_{3-5})sykloalkylen; hvori asteriskene indikerer bindingen som er bundet til -CO-$\mathbf{R^{O1}}$-gruppen; og

▪ $\mathbf{R^{O1}}$ representerer

• -OH;

• -O-(C_{1-4})alkyl;

• -NH-SO_2-$\mathbf{R^{S3}}$ hvori $\mathbf{R^{S3}}$ representerer (C_{1-4})alkyl, (C_{3-6})sykloalkyl hvori (C_{3-6})sykloalkylet eventuelt inneholder et ringoksygenatom, (C_{3-6})sykloalkyl-(C_{1-3})alkylen hvori (C_{3-6})sykloalkylet eventuelt inneholder et ringoksygenatom, (C_{1-3})fluoralkyl, fenyl eller -NH_2;

• -O-fenyl;

• -O-CH_2-CO-$\mathbf{R^{O4}}$, hvori $\mathbf{R^{O4}}$ representerer hydroksy, eller (C_{1-4})alkoksy eller -N[(C_{1-4})alkyl]$_2$;

• -O-CH_2-O-CO-$\mathbf{R^{O5}}$, hvori $\mathbf{R^{O5}}$ representerer (C_{1-4})alkyl eller (C_{1-4})alkoksy;

• -O-CH_2-CH_2-N[(C_{1-4})alkyl]$_2$; eller

• (5-metyl-2-okso-[1,3]dioksol-4-yl)-metyloksy-;

• -CO-CH_2-CN;

• -CO-CH_2-OH;

• -CO-H;

•



•



• 2-hydroksy-3,4-diokso-syklobut-1-enyl;

• hydroksy-(C_{1-4})alkyl;

• dihydroksy-(C_{2-4})alkyl;

• hydroksy-(C_{2-4})alkoksy;

• (C_{1-4})alkoksy-(C_{2-4})alkoksy;

• -(CH_2)$_m$-N$\mathbf{R^{N1}}$$\mathbf{R^{N2}}$, hvori **m** representerer heltallet 0 eller 1; og hvori

▪ $\mathbf{R^{N1}}$ og $\mathbf{R^{N2}}$ uavhengig representerer hydrogen, (C_{1-4})alkyl, (C_{1-4})alkoksy-(C_{2-4})alkyl, (C_{3-6})sykloalkyl, (C_{2-3})fluoralkyl, eller -SO_2-(C_{1-4})alkyl;

▪ eller $\mathbf{R^{N1}}$ uavhengig representerer hydrogen eller (C_{1-4})alkyl, og $\mathbf{R^{N2}}$ uavhengig representerer -CO-H, -CO-(C_{1-3})alkyl, -CO-(C_{1-3})alkylen-OH eller -CO-O-(C_{1-3})alkyl;

▪ eller $\mathbf{R^{N1}}$ og $\mathbf{R^{N2}}$ sammen med nitrogenet de er festet til danner en 4-, 5- eller 6-leddet mettet ring som eventuelt inneholder ett ringoksygen- eller ringsvovelatom, hvori ringen er usubstituert, eller mono-substituert med okso på et ringkarbonatom, eller di-substituert med okso på et ringsvovelatom;

• -CO-N$\mathbf{R^{N3}R^{N4}}$ hvori $\mathbf{R^{N3}}$ og $\mathbf{R^{N4}}$ uavhengig representerer hydrogen, (C_{1-4})alkyl, hydroksy-(C_{2-4})alkyl, (C_{1-3})alkoksy-(C_{2-4})alkyl, dimetylamino-(C_{2-4})alkyl, (C_{1-4})alkoksy, hydroksy-(C_{2-4})alkoksy, benzyloksy eller hydroksy;

• -NH-CO-N$\mathbf{R^{N5}R^{N6}}$ hvori $\mathbf{R^{N5}}$ og $\mathbf{R^{N6}}$ uavhengig representerer hydrogen eller (C_{1-4})alkyl;

• -SO_2-$\mathbf{R^{S1}}$ hvori $\mathbf{R^{S1}}$ representerer hydroksy, (C_{1-4})alkyl, eller -N$\mathbf{R^{N7}R^{N8}}$ hvori $\mathbf{R^{N7}}$ og $\mathbf{R^{N8}}$ uavhengig representerer hydrogen eller (C_{1-3})alkyl;

• 5-okso-4,5-dihydro-[1,2,4]oksadiazol-3-yl eller 3-okso-2,3-dihydro-[1,2,4]oksadiazol-5-yl;

• benzooksazol-2-yl; eller

• -(CH_2)$_\mathbf{p}$-**HET**, hvori **p** representerer heltallet 0 eller 1; og hvori **HET** representerer et 5- eller 6-leddet heteroaryl, hvori det 5- eller 6-leddede heteroarylet er usubstituert, eller mono- eller di-substituert, hvori substituentene er uavhengig valgt fra (C_{1-4})alkyl, (C_{1-4})alkoksy, -COOH, hydroksy, fluor, 2-amino-2-okso-etyl, 2-karboksy-etyl, (C_{3-5})sykloalkyl, eller -N$\mathbf{R^{N9}R^{N10}}$ hvori $\mathbf{R^{N9}}$ og $\mathbf{R^{N10}}$ uavhengig representerer hydrogen eller (C_{1-3})alkyl;
og den gjenværende ene eller to av substituentene, hvis til stede, er uavhengig valgt fra

• (C_{1-6})alkyl;

• (C_{1-4})alkoksy;

• (C_{1-3})fluoralkyl;

• (C_{1-3})fluoralkoksy:

• halogen;

• (C_{3-6})sykloalkyl;

• (C_{3-6})sykloalkyl-oksy;

• hydroksy;

• nitro;

• -(CH_2)$_m$-N$\mathbf{R}^{N1}\mathbf{R}^{N2}$, hvori **m** representerer heltallet 0 eller 1; og hvori $\mathbf{R}^{N1}$ og $\mathbf{R}^{N2}$ uavhengig representerer hydrogen, (C_{1-4})alkyl, (C_{1-4})alkoksy-(C_{2-4})alkyl, (C_{3-6})sykloalkyl, (C_{2-3})fluoralkyl eller -SO_2-(C_{1-4})alkyl; eller $\mathbf{R}^{N1}$ og $\mathbf{R}^{N2}$ sammen med nitrogenet som de er festet til, danner en 5- eller 6-leddet mettet ring som eventuelt inneholder ett ringoksygen- eller ringsvovelatom, hvori ringen er usubstituert eller mono-substituert med okso på et ringkarbonatom, eller di-substituert med okso på et ringsvovelatom;

• -S-$\mathbf{R}^{S2}$ hvori $\mathbf{R}^{S2}$ representerer (C_{1-4})alkyl, (C_{3-6})sykloalkyl eller 2-fluor-vinyl; eller

• fenyl-oksy, hvori fenylet eventuelt er mono-substituert med halogen;

• eller $\mathbf{Ar}^{1}$ representerer 8- til 10-leddet bisyklisk heteroaryl; hvori det 8- til 10-leddede bisykliske heteroarylet uavhengig er usubstituert, mono-, di- eller tri-substituert, hvori substituentene er uavhengig valgt fra (C_{1-4})alkyl; (C_{1-4})alkoksy; (C_{1-3})fluoralkyl; halogen; og -(C_{0-3})alkylen-COO$\mathbf{R}^{O2}$ hvori $\mathbf{R}^{O2}$ representerer hydrogen eller (C_{1-4})alkyl;

• eller $\mathbf{Ar}^{1}$ representerer 8- til 10-leddet delvis aromatisk fusert bisyklisk heterosyklyl omfattende ett til fire heteroatomer uavhengig valgt fra nitrogen, oksygen og svovel; hvori det 8- til 10-leddede heterosyklylet er bundet til resten av molekylet ved den aromatiske ringdelen; hvori det 8- til 10-leddede heterosyklylet uavhengig er usubstituert, mono- eller di-substituert, hvori substituentene er uavhengig valgt fra okso, (C_{1-6})alkyl og -(C_{0-3})alkylen-COO$\mathbf{R}^{O3}$ hvori $\mathbf{R}^{O3}$ representerer hydrogen eller (C_{1-3})alkyl;

eller et farmasøytisk akseptabelt salt derav.

5. Forbindelse ifølge et hvilket som helst av kravene 1 til 3, hvori **Ar^1** representerer

• en fenylgruppe av strukturen (Ar-IV):

(Ar-IV)

hvori

• **R^p** representerer;

- (C_{4-6})sykloalkyl som inneholder et ringoksygenatom, hvori (C_{4-6})sykloalkylet som inneholder et ringoksygenatom er usubstituert eller mono-substituert med fluor, hydroksy eller metoksy;

- hydroksy;

- -**X^1**-CO-**R^{O1}**, hvori

- **X^1** representerer en direktebinding, (C_{1-3})alkylen, -O-(C_{1-3})alkylen-*, -NH-(C_{1-3})alkylen-*, -S-CH_2-*, -CF_2-, -CH=CH-, -C=C-, -NH-CO-*, -CO- eller (C_{3-5})sykloalkylen; hvori asteriskene indikerer bindingen som er bundet til -CO-**R^{O1}**-gruppen; og

- $\mathbf{R^{O1}}$ representerer

  - -OH;

  - -O-(C_{1-4})alkyl;

  - -NH-SO_2-$\mathbf{R^{S3}}$ hvori $\mathbf{R^{S3}}$ representerer (C_{1-4})alkyl, (C_{3-6})sykloalkyl hvori (C_{3-6})sykloalkylet eventuelt inneholder et ringoksygenatom, (C_{3-6})sykloalkyl-(C_{1-3})alkylen hvori (C_{3-6})sykloalkylet eventuelt inneholder et ringoksygenatom, (C_{1-3})fluoralkyl, fenyl eller -NH_2;

  - -O-CH_2-CO-$\mathbf{R^{O4}}$, hvori $\mathbf{R^{O4}}$ representerer hydroksy eller (C_{1-4})alkoksy eller -N[(C_{1-4})alkyl]$_2$:

  - -O-CH_2-O-CO-$\mathbf{R^{O5}}$, hvori $\mathbf{R^{O5}}$ representerer (C_{1-4})alkyl eller (C_{1-4})alkoksy;

  - -O-CH_2-CH_2-N[(C_{1-4})alkyl]$_2$; eller

  - (5-metyl-2-okso-[1,3]dioksol-4-yl)-metyloksy-;

- -CO-H;

- 

- 2-hydroksy-3,4-diokso-syklobut-1-enyl;

-N$\mathbf{R^{N1}R^{N2}}$, hvori

▪ $\mathbf{R^{N1}}$ uavhengig representerer hydrogen eller (C_{1-4})alkyl, og $\mathbf{R^{N2}}$ uavhengig representerer -CO-H, -CO-(C_{1-3})alkyl eller -CO-(C_{1-3})alkylen-OH;

-CO-N$\mathbf{R^{N3}R^{N4}}$ hvori $\mathbf{R^{N3}}$ og $\mathbf{R^{N4}}$ uavhengig representerer hydrogen, (C_{1-4})alkyl, hydroksy-(C_{2-4})alkyl, (C_{1-3})alkoksy-(C_{2-4})alkyl eller hydroksy;

-NH-CO-N$\mathbf{R^{N5}R^{N6}}$ hvori $\mathbf{R^{N5}}$ og $\mathbf{R^{N6}}$ uavhengig representerer hydrogen eller (C_{1-4})alkyl;

5-okso-4,5-dihydro-[1,2,4]oksadiazol-3-yl eller 3-okso-2,3-dihydro-[1,2,4]oksadiazol-5-yl;

HET, hvori **HET** representerer et 5- eller 6-leddet heteroaryl, hvori det 5- eller 6-leddede heteroarylet er usubstituert, eller mono- eller di-substituert, hvori substituentene er uavhengig valgt fra (C_{1-4})alkyl, (C_{1-4})alkoksy, -COOH, hydroksy, fluor, 2-amino-2-okso-etyl, 2-karboksy-etyl, (C_{3-5})sykloalkyl eller -N$\mathbf{R^{N9}R^{N10}}$ hvori $\mathbf{R^{N9}}$ og $\mathbf{R^{N10}}$ uavhengig representerer hydrogen eller (C_{1-3})alkyl;

• $\mathbf{R^{m1}}$ representerer

(C_{1-6})alkyl;

- (C_{1-4})alkoksy;

- (C_{1-3})fluoralkyl;

- (C_{1-3})fluoralkoksy;

- halogen;

- (C_{3-6})sykloalkyl;

- (C_{3-6})sykloalkyl-oksy;

- -N$\mathbf{R^{N1}R^{N2}}$, hvori $\mathbf{R^{N1}}$ og $\mathbf{R^{N2}}$ uavhengig representerer hydrogen, (C_{1-4})alkyl eller (C_{3-6})sykloalkyl; eller

- -S-$\mathbf{R^{S2}}$ hvori $\mathbf{R^{S2}}$ representerer (C_{1-4})alkyl, (C_{3-6})sykloalkyl eller 2-fluor-vinyl; og

• $\mathbf{R^{m2}}$ representerer hydrogen, fluor eller klor;

• eller **R^p** representerer hydrogen;

R^{m1} representerer 1H-pyrazol-1-yl; eller -**X^1**-COOH, hvori **X^1** representerer en direktebinding, (C_{1-3})alkylen eller -O-(C_{1-3})alkylen-*, hvori asteriskene indikerer at bindingen er bundet til -COOH-gruppen;

og **R^{m2}** representerer hydrogen, (C_{1-4})alkoksy; eller -S-(C_{1-4})alkyl;

• eller **Ar^1** representerer en 5-leddet heteroarylgruppe av strukturen (Ar-II):



(Ar-II)

hvori i (Ar-II) representerer ringen A en tiofenyl- eller en tiazolylring;

hvori

• R^7 representerer

- 3-hydroksy-oksetan-3-yl;
- hydroksy;
- 2,2,2-trifluor-1,1-dihydroksy-etyl;
- -**X^1**-CO-**R^{O1}**, hvori
- **X^1** representerer en direktebinding, (C_{1-3})alkylen, -O-(C_{1-3})alkylen-*, -NH-(C_{1-3})alkylen-*, -S-CH_2-*, -CF_2-, -CH=CH-, -C=C-, -NH-CO-*, -CO- eller (C_{3-}

$_5$)sykloalkylen; hvori asteriskene indikerer bindingen som er bundet til -CO-**R^{O1}**-gruppen; og

R^{O1} representerer

- -OH;
- -O-(C_{1-4})alkyl;
- -NH-SO_2-**R^{S3}** hvori **R^{S3}** representerer (C_{1-4})alkyl, (C_{3-6})sykloalkyl hvori (C_{3-6})sykloalkylet eventuelt inneholder et ringoksygenatom, (C_{3-6})sykloalkyl-(C_{1-3})alkylen hvori (C_{3-6})sykloalkylet eventuelt inneholder et ringoksygenatom, (C_{1-3})fluoralkyl, fenyl eller -NH_2;
- -O-fenyl;
- -O-CH_2-CO-**R^{O4}**, hvori **R^{O4}** representerer hydroksy, eller (C_{1-4})alkoksy eller -N[(C_{1-4})alkyl]$_2$;
- -O-CH_2-O-CO-**R^{O5}**, hvori **R^{O5}** representerer (C_{1-4})alkyl eller (C_{1-4})alkoksy;
- -O-CH_2-CH_2-N[(C_{1-4})alkyl]$_2$; eller
- (5-metyl-2-okso-[1,3]dioksol-4-yl)-metyloksy-;

-CO-CH_2-OH;

-CO-H;



- hydroksy-(C_{1-4})alkyl;

- -N$\mathbf{R^{N1}R^{N2}}$, hvori

▪ $\mathbf{R^{N1}}$ og $\mathbf{R^{N2}}$ uavhengig representerer hydrogen, (C_{1-4})alkyl eller (C_{3-6})sykloalkyl;

▪ eller $\mathbf{R^{N1}}$ uavhengig representerer hydrogen eller (C_{1-4})alkyl, og $\mathbf{R^{N2}}$ uavhengig representerer -CO-H, -CO-(C_{1-3})alkyl eller -CO-(C_{1-3})alkylen-OH;

- -CO-N$\mathbf{R^{N3}R^{N4}}$ hvori $\mathbf{R^{N3}}$ og $\mathbf{R^{N4}}$ uavhengig representerer hydrogen, (C_{1-4})alkyl, hydroksy-(C_{2-4})alkyl, (C_{1-3})alkoksy-(C_{2-4})alkyl, dimetylamino-(C_{2-4})alkyl, (C_{1-4})alkoksy, hydroksy-(C_{2-4})alkoksy, benzyloksy eller hydroksy;

- -NH-CO-N$\mathbf{R^{N5}R^{N6}}$ hvori $\mathbf{R^{N5}}$ og $\mathbf{R^{N6}}$ uavhengig representerer hydrogen eller (C_{1-4})alkyl;

- 5-okso-4,5-dihydro-[1,2,4]oksadiazol-3-yl eller 3-okso-2,3-dihydro-[1,2,4]oksadiazol-5-yl; eller

-

HET, hvori **HET** representerer et 5- eller 6-leddet heteroaryl, hvori det 5- eller 6-leddede heteroarylet er usubstituert, eller mono- eller di-substituert, hvori substituentene er uavhengig valgt fra (C_{1-4})alkyl, (C_{1-4})alkoksy, -COOH, hydroksy, fluor, 2-amino-2-okso-etyl, 2-karboksy-etyl, (C_{3-5})sykloalkyl eller -N$\mathbf{R^{N9}R^{N10}}$ hvori $\mathbf{R^{N9}}$ og $\mathbf{R^{N10}}$ uavhengig representerer hydrogen eller (C_{1-3})alkyl;

• og ($\mathbf{R^6}$)$_\mathbf{n}$ representerer en valgfri substituent uavhengig valgt fra

- (C_{1-6})alkyl:
- (C_{1-4})alkoksy;
- (C_{1-3})fluoralkyl;
- (C_{1-3})fluoralkoksy;
- halogen;
- (C_{3-6})sykloalkyl;
- (C_{3-6})sykloalkyl-oksy;

- hydroksy;

- pyridinyl; og

- -N$\mathbf{R^{N1}R^{N2}}$, hvori $\mathbf{R^{N1}}$ og $\mathbf{R^{N2}}$ uavhengig representerer hydrogen, (C_{1-4})alkyl eller (C_{3-6})sykloalkyl;

• eller $\mathbf{Ar^1}$ representerer 9- eller 10-leddet bisyklisk heteroaryl; hvori det 9- eller 10-leddede bisykliske heteroarylet uavhengig er usubstituert, mono- eller di-substituert, hvori substituentene er uavhengig valgt fra (C_{1-4})alkyl; (C_{1-4})alkoksy; (C_{1-3})fluoralkyl; (C_{1-3})fluoralkoksy; halogen; cyano; hydroksy eller -(C_{0-3})alkylen-COO$\mathbf{R^{O2}}$ hvori $\mathbf{R^{O2}}$ representerer hydrogen eller (C_{1-4})alkyl;

• eller $\mathbf{Ar^1}$ representerer en gruppe av strukturen (Ar-III):



(Ar-III)

hvori ringen (B) representerer en ikke-aromatisk 5- eller 6-leddet ring fusert til fenylgruppen, hvori ring (B) omfatter ett eller to heteroatomer uavhengig valgt fra nitrogen og oksygen; hvori ringen (B) uavhengig er usubstituert, mono- eller di-substituert, hvori substituentene er uavhengig valgt fra okso, (C_{1-6})alkyl og -(C_{0-3})alkylen-COO$\mathbf{R^{O3}}$ hvori $\mathbf{R^{O3}}$ representerer hydrogen eller (C_{1-3})alkyl: eller et farmasøytisk akseptabelt salt derav.

6. Forbindelse ifølge et hvilket som helst av kravene 1 til 3; hvori

• **Ar^1** representerer en fenylgruppe valgt fra:

a)



og

eller

b)



og



eller

c)



;

eller

d)





og

• eller **Ar[1]** representerer en tiofenylgruppe valgt fra:

a)



og

eller

b)


og

: eller

c)





og

:

• eller **Ar^1** representerer en tiazoylgruppe valgt fra:


og

:

• eller **Ar^1** representerer 9- eller 10-leddet bisyklisk heteroaryl valgt fra

a)


:

eller

b)



og



• eller **Ar[1]** representerer en gruppe valgt fra:

a)



eller

b)



og



eller et farmasøytisk akseptabelt salt derav.

7. Forbindelse ifølge et hvilket som helst av kravene 1 til 6; hvori gruppen



representerer



hvori

R2 representerer metyl, klor eller cyano; og

R13 representerer hydrogen; og

• **R14**, **R15**, **R16** og **R17** uavhengig representerer følgende:

R14 representerer hydrogen, metyl, etyl, metoksy, brom, klor, fluor, trifluormetyl, trifluormetoksy eller cyano;

R15 representerer hydrogen, metyl, metoksy, klor, fluor;

R16 representerer hydrogen, metoksy eller fluor; og

R17 representerer hydrogen, metyl, metoksy, klor, fluor eller cyano;

hvori minst én av **R14**, **R15**, **R16** og **R17** representerer hydrogen;

• eller **R14** og **R15** sammen danner en gruppe -O-CH_2-O-, **R16** representerer hydrogen og **R17** representerer hydrogen eller halogen;

eller

R2 representerer (C_{1-3})alkyl, halogen eller cyano; og

R13 representerer fluor; og

• **R14**, **R15**, **R16** og **R17** uavhengig representerer følgende:

R14 representerer hydrogen, metyl, etyl, metoksy, brom, klor, fluor, trifluormetyl, trifluormetoksy eller cyano;

R15 representerer hydrogen, metyl, metoksy, klor, fluor;

R^{16} representerer hydrogen, metoksy eller fluor; og

R^{17} representerer hydrogen, metyl, metoksy, klor, fluor eller cyano;

hvori minst to av **R^{14}**, **R^{15}**, **R^{16}** og **R^{17}** representerer hydrogen
eller et farmasøytisk akseptabelt salt derav.

8. Forbindelse ifølge et hvilket som helst av kravene 1 til 6; hvori gruppen



representerer en gruppe valgt fra de følgende gruppene A), B), C), D) og E):

A)



og



:

B)



og

:

C)



og

D)



og

E)



og

eller et farmasøytisk akseptabelt salt derav.

9. Forbindelse ifølge krav 1, som er en forbindelse av formel (II)



Formel (II)

hvori

R^2 representerer metyl, klor eller cyano; og

• **R^{14}**, **R^{15}**, **R^{16}** og **R^{17}** uavhengig representerer følgende:

R^{14} representerer metyl, metoksy, halogen eller cyano;

R^{15} representerer hydrogen, metyl, klor eller fluor;

R^{16} representerer hydrogen eller fluor; og

R^{17} representerer hydrogen, klor eller fluor;
hvori minst én av **R^{15}**, **R^{16}** og **R^{17}** representerer hydrogen og **Ar^1** representerer

• en fenylgruppe av strukturen (Ar-IV):



(Ar-IV)

hvori

• **R^p** representerer;

hydroksy;

- -COOH;

- -CO-CH_2-CN;

- -CO-(C_{1-4})alkoksy;

- -CO-NH-SO_2-$\mathbf{R^{S3}}$ hvori $\mathbf{R^{S3}}$ representerer $\mathbf{R^{S3}}$ representerer (C_{1-4})alkyl, (C_{3-6})sykloalkyl; (C_{3-6})sykloalkyl-(C_{1-3})alkyl; (C_{1-3})fluoralkyl, fenyl eller -NH_2;

- -$\mathbf{X^1}$-CH_2-COOH, hvori $\mathbf{X^1}$ representerer O eller NH;

- -CO-N$\mathbf{R^{N3}R^{N4}}$ hvori $\mathbf{R^{N3}}$ og $\mathbf{R^{N4}}$ uavhengig representerer hydrogen, (C_{1-4})alkyl, hydroksy-(C_{2-4})alkyl, (C_{1-3})alkoksy-(C_{2-4})alkyl, dimetylamino-(C_{2-4})alkyl, (C_{1-4})alkoksy eller hydroksy-(C_{2-4})alkoksy;

- -NH-CO-N$\mathbf{R^{N5}R^{N6}}$ hvori $\mathbf{R^{N5}}$ og $\mathbf{R^{N6}}$ uavhengig representerer hydrogen eller (C_{1-4})alkyl;

- -SO_2-$\mathbf{R^{S1}}$ hvori $\mathbf{R^{S1}}$ representerer hydroksy, (C_{1-4})alkyl eller -N$\mathbf{R^{N7}R^{N8}}$ hvori $\mathbf{R^{N7}}$ og $\mathbf{R^{N8}}$ uavhengig representerer hydrogen eller (C_{1-3})alkyl;

- 5-okso-4,5-dihydro-[1,2,4]oksadiazol-3-yl;

- tetrazolyl (særlig 1H-tetrazol-5-yl); eller

- 5- eller 6-leddet heteroaryl valgt fra oksazolyl, isoksazolyl, oksadiazolyl, tiazolyl, isotiazolyl, tiadiazolyl, imidazolyl, pyrazolyl, triazolyl, pyridinyl, pyrimidinyl, pyridazinyl eller pyrazinyl; hvori det 5- eller 6-leddede heteroarylet er usubstituert eller mono- eller di-substituert, hvori substituentene er uavhengig valgt fra (C_{1-3})alkyl, (C_{1-3})alkoksy, -COOH, hydroksy, fluor, 2-amino-2-okso-etyl, 2-karboksy-etyl eller -N$\mathbf{R^{N9}R^{N10}}$ hvori $\mathbf{R^{N9}}$ og $\mathbf{R^{N10}}$ uavhengig representerer hydrogen eller (C_{1-3})alkyl;

• $\mathbf{R^{m1}}$ representerer

- hydrogen;

- (C_{1-6})alkyl;

- (C_{1-4})alkoksy;

- (C_{1-3})fluoralkyl;

- (C_{1-3})fluoralkoksy;

- halogen;

- (C_{3-6})sykloalkyl;

- (C_{3-6})sykloalkyl-oksy;

- hydroksy;

- -$(CH_2)_m$-N$\mathbf{R^{N1}R^{N2}}$, hvori **m** representerer heltallet 0 eller 1; og hvori $\mathbf{R^{N1}}$ og $\mathbf{R^{N2}}$ uavhengig representerer hydrogen, (C_{1-3})alkyl eller (C_{2-3})fluoralkyl; eller $\mathbf{R^{N1}}$ og $\mathbf{R^{N2}}$ sammen med nitrogenet som de er festet til danner en pyrrolidinylring; eller

- -S-$\mathbf{R^{S2}}$ hvori $\mathbf{R^{S2}}$ representerer (C_{1-4})alkyl eller (C_{3-6})sykloalkyl;

• og $\mathbf{R^{m2}}$ representerer

- hydrogen; eller

- (C_{1-6})alkyl;

- (C_{1-3})alkoksy; eller

- halogen;

• eller **Ar^1** representerer en 5-leddet heteroarylgruppe av strukturen (Ar-V):



(Ar-V)

hvori i (Ar-V) representerer ringen A en tiofenyl- eller en tiazolylring;
hvori **R^{A1}** representerer

- -COOH;

- tetrazolyl;

- -CO-(C_{1-4})alkoksy;

- -CO-NH-SO_2-**R^{S3}** hvori **R^{S3}** representerer **R^{S3}** representerer (C_{1-4})alkyl, (C_{3-6})sykloalkyl; (C_{3-6})sykloalkyl-(C_{1-3})alkyl; (C_{1-3})fluoralkyl, fenyl eller -NH_2;

- -$\mathbf{X^1}$-CH_2-COOH, hvori $\mathbf{X^1}$ representerer O eller NH; eller

- -CO-N$\mathbf{R^{N3}R^{N4}}$ hvori $\mathbf{R^{N3}}$ og $\mathbf{R^{N4}}$ uavhengig representerer hydrogen, (C_{1-4})alkyl, hydroksy-(C_{2-4})alkyl eller (C_{1-3})alkoksy-(C_{2-4})alkyl;
og $\mathbf{R^{A2}}$ representerer

- hydrogen;

- (C_{1-6})alkyl;

- (C_{1-4})alkoksy;

- (C_{1-3})fluoralkyl;

- halogen; eller

- hydroksy;

• eller $\mathbf{Ar^1}$ representerer 9- eller 10-leddet bisyklisk heteroaryl valgt fra 1H-indol-5-yl, 1H-indol-4-yl, 1H-indol-6-yl, indazol-6-yl, 1H-benzoimidazol-5-yl,

1H-benzotriazol-5-yl, kinoksalin-6-yl, isokinolin-7-yl og kinolin-6-yl; hvori det 9- eller 10-leddede bisykliske heteroarylet uavhengig er usubstituert, mono- eller di-substituert, hvori substituentene er uavhengig valgt fra (C_{1-4})alkyl eller -COOH;

• eller **Ar^1** representerer en gruppe av strukturen (Ar-III):



(Ar-III)

hvori ring (B) representerer en ikke-aromatisk 5-leddet ring fusert til fenylgruppen, hvori ring (B) omfatter ett eller to nitrogenringatomer; hvori ringen (B) uavhengig er usubstituert, mono- eller di-substituert, hvori substituentene er uavhengig valgt fra okso og (C_{1-6})alkyl;
eller et farmasøytisk akseptabelt salt derav.

10. Forbindelse ifølge krav 1, som er en forbindelse av formel (III):



Formel (III)
hvori gruppen:



representerer en gruppe valgt fra de følgende gruppene A), B), C), D) og E):

A)



og

:

B)



og

:

C)



og

:

D)



;

E)





og

:

og

Ar[1] representerer

• fenyl eller 5-leddet heteroaryl valgt fra tiofenyl og tiazolyl; hvori fenylet eller det 5-leddede heteroarylet uavhengig er mono-, di- eller tri-substituert; hvori én av substituentene er valgt fra

• -$\mathbf{X^1}$-CO-$\mathbf{R^{O1}}$, hvori

▪ $\mathbf{X^1}$ representerer en direktebinding, -CH_2-CH_2-, -O-CH_2-*, -NH-CH_2-*, -CH=CH- eller -NH-CO-*; hvori asteriskene indikerer bindingen som er bundet til -CO-$\mathbf{R^{O1}}$-gruppen; og

▪ $\mathbf{R^{O1}}$ representerer

• -OH;

• -O-(C_{1-4})alkyl;

• -NH-SO_2-$\mathbf{R^{S3}}$ hvori $\mathbf{R^{S3}}$ representerer (C_{1-3})alkyl, syklopropyl eller -NH_2;

• -O-CH_2-CO-$\mathbf{R^{O4}}$, hvori $\mathbf{R^{O4}}$ representerer hydroksy eller (C_{1-4})alkoksy: eller

• -O-CH_2-O-CO-$\mathbf{R^{O5}}$, hvori $\mathbf{R^{O5}}$ representerer (C_{1-4})alkyl eller (C_{1-4})alkoksy:

• -N$\mathbf{R^{N1}R^{N2}}$, hvori $\mathbf{R^{N1}}$ uavhengig representerer hydrogen eller (C_{1-3})alkyl, og $\mathbf{R^{N2}}$ representerer -CO-H;

• 5-okso-4,5-dihydro-[1,2,4]oksadiazol-3-yl, eller 3-okso-2,3-dihydro-[1,2,4]oksadiazol-5-yl;

• 1H-tetrazol-5-yl;

• 3-hydroksy-isoksazol-5-yl;

• imidazolyl, som er usubstituert eller mono- eller di-substituert med metyl;

• pyrazolyl;

• isoksazolyl, oksazolyl eller tiadiazolyl; hvori isoksazolylet, oksazolylet eller tiadiazolylet er mono-substituert med -N$\mathbf{R^{N9}R^{N10}}$, hvori $\mathbf{R^{N9}}$ representerer

hydrogen, og $\mathbf{R^{N10}}$ representerer hydrogen eller metyl; og den gjenværende ene eller to av substituentene (hvis til stede), er uavhengig valgt fra

• (C_{1-4})alkyl;

• (C_{1-4})alkoksy;

• 2,2,2-trifluoretoksy;

• halogen;

• -N$\mathbf{R^{N1}R^{N2}}$, hvori $\mathbf{R^{N1}}$ representerer hydrogen, og $\mathbf{R^{N2}}$ representerer (C_{1-3})alkyl;

• -S-$\mathbf{R^{S2}}$ hvori $\mathbf{R^{S2}}$ representerer (C_{1-4})alkyl;

• eller $\mathbf{Ar^1}$ representerer 8- til 10-leddet bisyklisk heteroaryl valgt fra usubstituert benzimidazol; usubstituert indazolyl, og indolyl som er usubstituert eller mono-substituert med -COO$\mathbf{R^{O2}}$ hvori $\mathbf{R^{O2}}$ representerer hydrogen eller (C_{1-4})alkyl;

• eller $\mathbf{Ar^1}$ representerer okso-substituert 8- til 10-leddet delvis aromatisk fusert bisyklisk heterosyklyl valgt fra 2-okso-2,3-dihydro-benzooksazolyl, 3-okso-2,3-dihydro-1H-indazolyl, 2-okso-1,2,3,4-tetrahydro-kinazolinyl, 1-okso-1,2,3,4-tetrahydro-isokinolinyl; hvori det okso-substituerte heterosyklylet er usubstituert eller mono-substituert på et ringnitrogenatom med (C_{1-3})alkyl;

eller et farmasøytisk akseptabelt salt derav.

11. Forbindelse ifølge krav 1, valgt fra gruppen som består av:

3-klor-5-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

5-{6-[2-(2-cyano-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

[6-(2,3-dihydro-1H-indol-5-yl)-pyrimidin-4-yl]-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-amin;

[2-(7-fluor-2,4-dimetyl-indol-1-yl)-etyl]-{6-[4-(1H-imidazol-4-yl)-fenyl]-pyrimidin-4-yl}-amin;

3-etyl-5-{6-[2-(6-fluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-metyl-tiofen-2-karboksylsyre;

5-{6-[2-(4-klor-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

3-etyl-5-{6-[2-(4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

3-klor-5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

4-{6-[2-(7-fluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-metylamino-benzosyre;

5-{6-[2-(5,7-difluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

{6-[4-(3-amino-isoksazol-5-yl)-fenyl]-pyrimidin-4-yl}-[2-(4-metoksy-2-metyl-indol-1-yl)-etyl]-amin;

[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-{6-[4-(1H-imidazol-4-yl)-fenyl]-pyrimidin-4-yl}-amin;

[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-{6-[4-(1H-imidazol-4-yl)-fenyl]-pyrimidin-4-yl}-amin;

[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-{6-[4-(2H-pyrazol-3-yl)-fenyl]-pyrimidin-4-yl}-amin;

3-etoksy-5-{6-[2-(4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

5-{6-[2-(6-klor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

3-etoksy-5-{6-[2-(7-fluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

3-etoksy-5-{6-[2-(7-fluor-2,5-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

3-etoksy-5-{6-[2-(6-fluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

3-etyl-5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

5-{6-[2-(4,6-diklor-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

5-{6-[2-(4-klor-6-fluor-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

5-{6-[2-(4-klor-7-fluor-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

5-{6-[2-(2-cyano-6-fluor-4-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-metylamino-benzosyre;

5-{6-[2-(7-klor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

3-etoksy-5-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

3-etoksy-5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

3-etoksy-5-{6-[2-(4,6,7-trifluor-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

3-etoksy-5-{6-[2-(4,5,7-trifluor-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

5-{6-[2-(6,7-difluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

{6-[4-(3-amino-isoksazol-5-yl)-fenyl]-pyrimidin-4-yl}-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-amin;

[2-(6,7-difluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-{6-[4-(1H-imidazol-4-yl)-fenyl]-pyrimidin-4-yl}-amin;

[2-(7-fluor-2,4-dimetyl-indol-1-yl)-etyl]-{6-[4-(5-metylamino-[1,3,4]tiadiazol-2-yl)-fenyl]-pyrimidin-4-yl}-amin;

5-{6-[2-(2-cyano-6-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

2-etylamino-4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-benzosyre;

5-{6-[2-(6,7-difluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

5-{6-[2-(6-fluor-2,4-dimetyl-indol-1-yl)-etylamino]-2-metyl-pyrimidin-4-yl}-3-trifluormetyl-tiofen-2-karboksylsyre;

5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-trifluormetyl-tiofen-2-karboksylsyre;

5-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-trifluormetyl-tiofen-2-karboksylsyre;

[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-{6-[4-(5-metylamino-[1,3,4]tiadiazol-2-yl)-fenyl]-pyrimidin-4-yl}-amin;

4-(4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenyl)-tiazol-2-karboksylsyre;

2-klor-4-{6-[2-(6-klor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-6-propyl-benzosyre;

2-klor-4-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-6-propyl-benzosyre;

5-{6-[2-(6,7-difluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-trifluormetyl-tiofen-2-karboksylsyre;

4-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-isobutyl-benzosyre;

5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-2-metyl-pyrimidin-4-yl}-3-trifluormetyl-tiofen-2-karboksylsyre;

5-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-2-metyl-pyrimidin-4-yl}-3-trifluormetyl-tiofen-2-karboksylsyre;

1-etyl-3-(4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-metoksy-fenyl)-urea;

{6-[4-(2-amino-oksazol-5-yl)-fenyl]-pyrimidin-4-yl}-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-amin;

{6-[4-(2-amino-oksazol-5-yl)-fenyl]-pyrimidin-4-yl}-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-amin;

2-(4-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenyl)-tiazol-4-karboksylsyre;

2-(4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenyl)-tiazol-4-karboksylsyre;

[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-{6-[4-(2-metyl-1H-imidazol-4-yl)-fenyl]-pyrimidin-4-yl}-amin;

[2-(6-fluor-2,4-dimetyl-indol-1-yl)-etyl]-{6-[4-(5-metylamino-[1,3,4]tiadiazol-2-yl)-fenyl]-pyrimidin-4-yl}-amin;

4-{6-[2-(2-cyano-6-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-isobutyl-benzosyre;

2-klor-4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-6-propoksy-benzosyre;

2-butoksy-4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-benzosyre;

{6-[4-(2-amino-oksazol-5-yl)-fenyl]-pyrimidin-4-yl}-[2-(6,7-difluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-amin;

[2-(6,7-difluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-{6-[4-(2-metyl-1H-imidazol-4-yl)-fenyl]-pyrimidin-4-yl}-amin;

[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-{6-[4-(5-metylamino-[1,3,4]tiadiazol-2-yl)-fenyl]-pyrimidin-4-yl}-amin;

{6-[3-etoksy-4-(1H-tetrazol-5-yl)-fenyl]-pyrimidin-4-yl]}-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-amin;

{6-[3-etylamino-4-(1H-tetrazol-5-yl)-fenyl]-pyrimidin-4-yl}-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-amin;

[2-(7-klor-4-metoksy-2-metyl-indol-1-yl)-etyl]-{6-[3-etylamino-4-(1H-tetrazol-5-yl)-fenyl]-pyrimidin-4-yl}-amin;

{6-[3-etylamino-4-(1H-tetrazol-5-yl)-fenyl]-pyrimidin-4-yl}-[2-(4-metoksy-2-metyl-indol-1-yl)-etyl]-amin;

{6-[3-etylamino-4-(1H-tetrazol-5-yl)-fenyl]-pyrimidin-4-yl}-[2-(7-fluor-2,4-dimetyl-indol-1-yl)-etyl]-amin;

3-butoksy-5-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

3-butoksy-5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

5-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-propoksy-tiofen-2-karboksylsyre;

5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-isopropoksy-tiofen-2-karboksylsyre;

5-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-isopropoksy-tiofen-2-karboksylsyre;

5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-propoksy-tiofen-2-karboksylsyre;

3-(4-{6-[2-(6,7-difluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenyl)-4H-[1,2,4]oksadiazol-5-on;

2-klor-4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-6-isobutoksy-benzosyre;

[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-[6-(1H-indol-5-yl)-pyrimidin-4-yl]-amin;

[2-(6,7-difluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-[6-(1H-indol-5-yl)-pyrimidin-4-yl]-amin;

6-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-1,2-dihydro-indazol-3-on;

4-{6-[2-(2-klor-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-benzosyre;

5-{6-[2-(2-klor-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

5-{6-[2-(4-brom-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-{6-[5-(1H-tetrazol-5-yl)-tiofen-2-yl]-pyrimidin-4-yl}-amin;

5-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-hydroksy-tiofen-2-karboksylsyre;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-isopropoksy-tiofen-2-karboksylsyre;

1-(2-{6-[3-etoksy-4-(1H-tetrazol-5-yl)-fenyl]-pyrimidin-4-ylamino}-etyl)-7-fluor-4-metoksy-1H-indol-2-karbonitril;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-trifluormetyl-tiofen-2-karboksylsyre;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-fluor-tiofen-2-karboksylsyre;

4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-benzosyre;

(4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-fenoksy)-eddiksyre;

N-(5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karbonyl)-metansulfonamid;

(2-etoksy-4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenoksy)-eddiksyre;

(2-etoksy-4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenylamino)-eddiksyre;

5-{6-[2-(2-cyano-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

N-(5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karbonyl)-benzensulfonamid;

Propan-2-sulfonsyre-(5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karbonyl)-amid;

Syklopropansulfonsyre-(5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karbonyl)-amid;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre metylamid;

Etansulfonsyre-(5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karbonyl)-amid;

7-fluor-1-(2-{6-[4-(1 H-imidazol-4-yl)-3-metoksy-fenyl]-pyrimidin-4-ylamino}-etyl)-4-metoksy-1 H-indol-2-karbonitril;

7-fluor-4-metoksy-1-(2-{6-[4-(5-metyl-1H-imidazol-4-yl)-fenyl]-pynmidin-4-ylamino}-etyl)-1H-indol-2-karbonitril;

1-(2-{6-[3-etoksy-4-((5-okso-4,5-dihydro-[1,2,4]oksadiazol-3-yl)-fenyl]-pyrimidin-4-ylamino}-etyl)-7-fluor-4-metoksy-1H-indol-2-karbonitril;

1-(2-{6-[4-(2,5-dimetyl-1H-imidazol-4-yl)-fenyl]-pyrimidin-4-ylamino}-etyl)-7-fluor-4-metoksy-1H-indol-2-karbonitril;

1-{2-[6-(3-etyl-4-hydroksy-fenyl)-pyrimidin-4-ylamino]-etyl}-7-fluor-4-metoksy-1H-indol-2-karbonitril;

1-(2-{6-[4-(1,5-dimetyl-1H-imidazol-4-yl)-fenyl]-pyrimidin-4-ylamino}-etyl)-7-fluor-4-metoksy-1H-indol-2-karbonitril;

1-(2-{6-[4-(1,2-dimetyl-1H-imidazol-4-yl)-fenyl]-pyrimidin-4-ylamino}-etyl)-7-fluor-4-metoksy-1H-indol-2-karbonitril;

7-fluor-1-(2-{6-[4-((5-okso-4,5-dihydro-[1,2,4]oksadiazol-3-yl)-fenyl]-pyrimidin-4-ylamino}-etyl)-4-metoksy-1H-indol-2-karbonitril;

7-fluor-1-(2-{6-[5-(3-hydroksy-oksetan-3-yl)-4-metoksy-tiofen-2-yl]-pyrimidin-4-ylamino}-etyl)-4-metoksy-1H-indol-2-karbonitril;

1-(2-{6-[4-(2-syklopropyl-1-metyl-1H-imidazol-4-yl)-fenyl]-pyrimidin-4-ylamino}-etyl)-7-fluor-4-metoksy-1H-indol-2-karbonitril;

(4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-trifluormetoksy-fenoksy)-eddiksyre;

7-fluor-1-(2-{6-[4-(3H-imidazol-4-yl)-fenyl]-pyrimidin-4-ylamino}-etyl)-4-metoksy-1H-indol-2-karbonitril;

3-(2-etoksy-4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenyl)-[1,2,4]oksadiazol-5(4H)-on;

7-fluor-1-(2-{6-[4-(3-okso-2,3-dihydro-1,2,4-oksadiazol-5-yl)-fenyl]-pyrimidin-4-ylamino}-etyl)-4-metoksy-1H-indol-2-karbonitril;

5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-(2,2,2-trifluor-etoksy)-tiofen-2-karboksylsyre;

(4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etyl-fenoksy)-eddiksyre;

3-(2-etoksy-4-{6-[2-(6-fluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenyl)-[1,2,4]oksadiazol-5(4H)-on;

2-butoksy-6-klor-4-(6-((2-(7-fluor-4-metoksy-2-metyl-1H-indol-1-yl)etyl-1,1,2,2-d4)amino)pyrimidin-4-yl)benzosyre;

5-{6-[2-(7-klor-5-fluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

5-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-(2,2,2-trifluor-etoksy)-tiofen-2-karboksylsyre;

2-(2-etoksy-4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenylamino)-propionsyre;

5-{6-[2-(2-cyano-3-fluor-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-trifluormetyl-tiofen-2-karboksylsyre;

5-{6-[2-(2-cyano-7-fluor-4-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-fluor-tiofen-2-karboksylsyre;

7-fluor-1-(2-{6-[4-(3-hydroksy-isoksazol-5-yl)-fenyl]-pyrimidin-4-ylamino}-etyl)-4-metoksy-1H-indol-2-karbonitril;

N-(4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-fenyl)-oksalamsyre;

7-fluor-1-(2-{6-[4-(3-hydroksy-isoksazol-5-yl)-3-metoksy-fenyl]-pyrimidin-4-ylamino}-etyl)-4-metoksy-1H-indol-2-karbonitril;

5-{6-[2-(2-cyano-7-fluor-4-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-trifluormetyl-tiofen-2-karboksylsyre;

(4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-fenylamino)-eddiksyre;

1-(2-{6-[4-(2-syklopropyl-1H-imidazol-4-yl)-fenyl]-pyrimidin-4-ylamino}-etyl)-7-fluor-4-metoksy-1H-indol-2-karbonitril;

5-{6-[2-(6-klor-7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

(4-{6-[2-(2-cyano-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-fenylamino)-eddiksyre;

7-fluor-1-{2-[6-(4-hydroksy-3-trifluormetoksy-fenyl)-pyrimidin-4-ylamino]-etyl}-4-metoksy-1H-indol-2-karbonitril;

1-{2-[6-(3-klor-4-hydroksy-fenyl)-pyrimidin-4-ylamino]-etyl}-7-fluor-4-metoksy-1H-indol-2-karbonitril;

5-{6-[2-(4,6-diklor-7-fluor-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

5-{6-[2-(6-klor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-isopropoksy-tiofen-2-karboksylsyre;

(4-{6-[2-(2-cyano-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-fenoksy)-eddiksyre;

5-{6-[2-(6-klor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

2-butoksy-4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-benzosyre;

4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-trifluormetoksy-fenol;

3-etoksy-5-{6-[2-(3-fluor-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

5-{6-[2-(2-cyano-3-fluor-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

(2-etoksy-4-{6-[2-(7-fluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenylamino)-eddiksyre;

2-butoksy-4-{6-[2-(6,7-difluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-benzosyre;

5-{6-[2-(2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-isopropoksy-tiofen-2-karboksylsyre;

5-{6-[2-(2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

3-(2-etoksy-4-{6-[2-(4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenyl)-[1,2,4]oksadiazol-5(4H)-on;

5-{6-[2-(4,6-diklor-2-cyano-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

5-{6-[2-(2-cyano-5,6-difluor-4-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

5-{6-[2-(2-cyano-7-fluor-4-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

5-{6-[2-(2-cyano-7-fluor-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

(4-{6-[2-(2-cyano-7-fluor-4-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-fenoksy)-eddiksyre;

(4-{6-[2-(2-cyano-7-fluor-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-fenylamino)-eddiksyre;

1-{2-[6-(3-etoksy-4-hydroksy-fenyl)-pyrimidin-4-ylamino]-etyl}-7-fluor-4-metoksy-1H-indol-2-karbonitril;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyreamid;

5-{6-[2-(2-cyano-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-fluor-tiofen-2-karboksylsyre;

5-{6-[2-(4-klor-2-cyano-6,7-difluor-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-fluor-tiofen-2-karboksylsyre;

2-butoksy-4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-6-fluor-benzosyre;

2-butoksy-6-klor-4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-benzosyre;

2-klor-4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-6-propoksy-benzosyre;

4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-fluor-6-propoksy-benzosyre;

5-{6-[2-(4-klor-2-cyano-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

5-{6-[2-(2-cyano-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-trifluormetyl-tiofen-2-karboksylsyre;

5-{6-[2-(4-klor-2-cyano-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-trifluormetyl-tiofen-2-karboksylsyre;

5-{6-[2-(4-klor-2-cyano-6,7-difluor-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-trifluormetyl-tiofen-2-karboksylsyre;

2-klor-4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-6-isobutoksy-benzosyre;

(4-{6-[2-(4-klor-2-cyano-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-fenylamino)-eddiksyre;

(4-{6-[2-(4-klor-2-cyano-6,7-difluor-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-fenylamino)-eddiksyre;

4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-difluormetoksy-benzosyre;

7-fluor-4-metoksy-1-{2-[6-(1-metyl-2-okso-1,2,3,4-tetrahydro-kinazolin-7-yl)-pyrimidin-4-ylamino]-etyl}-1H-indol-2-karbonitril;

7-fluor-4-metoksy-1-{2-[6-(1-metyl-3-okso-2,3-dihydro-1H-indazol-6-yl)-pyrimidin-4-ylamino]-etyl}-1H-indol-2-karbonitril;

3-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-5-etylsulfanyl-benzosyre;

7-fluor-4-metoksy-1-(2-{6-[4-(3H-[1,2,3]triazol-4-yl)-fenyl]-pyrimidin-4-ylamino}-etyl)-1H-indol-2-karbonitril;

3-(3-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-5-etoksy-fenoksy)-propionsyre;

3-(4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-fenoksy)-propionsyre;

4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-3-fluor-benzosyre;

4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-benzensulfonamid;

1-(2-{6-[3-etoksy-4-(3H-[1,2,3]triazol-4-yl)-fenyl]-pyrimidin-4-ylamino}-etyl)-7-fluor-4-metoksy-1H-indol-2-karbonitril;

3-(5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-yl)-propionsyre;

7-fluor-1-(2-{6-[4-(2-hydroksy-3,4-diokso-syklobut-1-enyl)-fenyl]-pyrimidin-4-ylamino}-etyl)-4-metoksy-1H-indol-2-karbonitril;

(4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-fenyl)-okso-eddiksyre;

4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-propylsulfanyl-benzosyre;

4-{6-[2-(2-cyano-6-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-propylsulfanyl-benzosyre;

4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-isopropylsulfanyl-benzosyre;

4-{6-[2-(2-cyano-6-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-isopropylsulfanyl-benzosyre;

4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-fluor-6-propyl-benzosyre;

5-{6-[2-(2-cyano-5,7-difluor-4-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

5-{6-[2-(2-cyano-6,7-difluor-4-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

5-{6-[2-(2-cyano-6,7-difluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

(4-{6-[2-(2-cyano-6,7-difluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-fenoksy)-eddiksyre;

(4-{6-[2-(2-cyano-6,7-difluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-fenylamino)-eddiksyre;

4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-propyl-benzosyre;

4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etyl-benzosyre;

4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-isobutoksy-benzosyre;

4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-propoksy-benzosyre;

4-{6-[2-(2-cyano-7-fluor-4-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etylsulfanyl-benzosyre;

4-{6-[2-(2-cyano-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etylsulfanyl-benzosyre;

4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etylsulfanyl-benzosyre;

4-{6-[2-(2-cyano-6-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etylsulfanyl-benzosyre;

4-{6-[2-(2-cyano-6,7-difluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etylsulfanyl-benzosyre;

4-{6-[2-(2-cyano-6,7-difluor-4-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-benzosyre;

4-{6-[2-(2-cyano-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-metylamino-benzosyre;

2-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-1H-indol-5-karboksylsyre;

7-fluor-1-{2-[6-(1H-indol-2-yl)-pyrimidin-4-ylamino]-etyl}-4-metoksy-1H-indol-2-karbonitril;

2-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-1H-indol-5-karboksylsyremetylester;

7-fluor-1-(2-{6-[4-(2-hydroksy-etoksy)-fenyl]-pyrimidin-4-ylamino}-etyl)-4-metoksy-1H-indol-2-karbonitril;

7-fluor-1-{2-[6-(1H-indol-6-yl)-pyrimidin-4-ylamino]-etyl}-4-metoksy-1H-indol-2-karbonitril;

7-fluor-4-metoksy-1-{2-[6-(1H-pyrrolo[2,3-c]pyridin-3-yl)-pyrimidin-4-ylamino]-etyl}-1H-indol-2-karbonitril;

7-fluor-1-{2-[6-(1 H-indol-3-yl)-pyrimidin-4-ylamino]-etyl}-4-metoksy-1H-indol-2-karbonitril;

7-fluor-4-metoksy-1-{2-[6-(2-okso-1,2,3,4-tetrahydro-kinazolin-6-yl)-pyrimidin-4-ylamino]-etyl}-1H-indol-2-karbonitril;

N-(4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenyl)-formamid;

7-fluor-4-metoksy-1-{2-[6-(2-okso-2,3-dihydro-benzooksazol-6-yl)-pyrimidin-4-ylamino]-etyl}-1H-indol-2-karbonitril;

7-fluor-4-metoksy-1-{2-[6-(3-metyl-2-okso-2,3-dihydro-benzooksazol-5-yl)-pyrimidin-4-ylamino]-etyl}-1H-indol-2-karbonitril;

7-fluor-1-{2-[6-(1H-indazol-5-yl)-pyrimidin-4-ylamino]-etyl}-4-metoksy-1H-indol-2-karbonitril;

7-fluor-4-metoksy-1-{2-[6-(1H-pyrrolo[2,3-b]pyridin-3-yl)-pyrimidin-4-ylamino]-etyl}-1H-indol-2-karbonitril;

7-fluor-4-metoksy-1-{2-[6-(1H-pyrrolo[2,3-b]pyridin-5-yl)-pyrimidin-4-ylamino]-etyl}-1H-indol-2-karbonitril;

7-fluor-4-metoksy-1-{2-[6-(1-metyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-pyrimidin-4-ylamino]-etyl}-1H-indol-2-karbonitril;

1-(4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-metoksy-fenyl)-3-etyl-urea;

1-{2-[6-(1H-benzoimidazol-5-yl)-pyrimidin-4-ylamino]-etyl}-7-fluor-4-metoksy-1H-indol-2-karbonitril;

1-{2-[6-(3H-benzotriazol-5-yl)-pyrimidin-4-ylamino]-etyl}-7-fluor-4-metoksy-1H-indol-2-karbonitril;

7-fluor-4-metoksy-1-{2-[6-(1-okso-1,2,3,4-tetrahydro-isokinolin-6-yl)-pyrimidin-4-ylamino]-etyl}-1H-indol-2-karbonitril;

1-{2-[6-(3-etoksy-4-formyl-fenyl)-pyrimidin-4-ylamino]-etyl}-7-fluor-4-metoksy-1H-indol-2-karbonitril;

7-fluor-1-{2-[6-(1H-indol-5-yl)-pyrimidin-4-ylamino]-etyl}-4-metoksy-1H-indol-2-karbonitril;

4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-fluor-benzosyremetylester;

7-fluor-1-{2-[6-(4-hydroksy-3-trifluormetyl-fenyl)-pyrimidin-4-ylamino]-etyl}-4-metoksy-1H-indol-2-karbonitril;

3-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-5-etoksy-benzosyre;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-3-karboksylsyreetylester;

4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-metylamino-benzosyre;

4-{6-[2-(5,7-difluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-metylamino-benzosyre;

3-(5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-isopropoksy-tiofen-2-yl)-propionsyre;

3-(3-etoksy-5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-yl)-propionsyre;

(E)-3-(3-etoksy-5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-yl)-akrylsyre;

4-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-metylamino-benzosyre;

3-klor-5-{6-[2-(4-klor-2-cyano-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

3-klor-5-{6-[2-(4-klor-2-cyano-6,7-difluor-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

N-(3-etoksy-5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karbonyl)-metansulfonamid;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyreetylamid;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyredimetylamid;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre-(2-hydroksy-etyl)-amid;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyreisopropylamid;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre-(2-metoksy-etyl)-amid;

5-(6-((2-(2-cyano-7-fluor-4-metoksy-1H-indol-1-yl)etyl)amino)pyrimidin-4-yl)-3-etoksy-N-sulfamoyltiofen-2-karboksamid;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyrehydroksyamid;

(3-etoksy-5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-yl)-metanol;

2-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-4-isopropoksy-tiazol-5-karboksylsyre;

2-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-4-metoksy-tiazol-5-karboksylsyre;

4-etoksy-2-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiazol-5-karboksylsyre;

2-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-4-propoksy-tiazol-5-karboksylsyre;

2-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-4-isobutyl-tiazol-5-karboksylsyre;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyrekarboksymetylester;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyredimetylkarbamoylmetylester;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyrebutyryloksymetylester;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyreetoksykarbonyloksymetylester;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre-5-metyl-2-okso-[1,3]dioksol-4-ylmetylester;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre-2-dimetylamino-etylester;

5-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyrefenylester;

(4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-metoksy-fenyl)-propenoinsyreetylester;

{6-[4-etoksy-5-(1H-tetrazol-5-yl)-tiofen-2-yl]-pyrimidin-4-yl}-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-amin;

3-etoksy-5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-N-hydroksy-tiofen-2-karboksamidin;

3-(3-etoksy-5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-yl)-[1,2,4]oksadiazol-5(4H)-on;

5-{6-[2-(3,7-difluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-{6-[5-(2H-tetrazol-5-yl)-4-trifluormetyl-tiofen-2-yl]-pyrimidin-4-yl}-amin;

5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-N-hydroksy-3-trifluormetyl-tiofen-2-karboksamidin;

3-(5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-trifluormetyl-tiofen-2-yl)-[1,2,4]oksadiazol-5(4H)-on;

4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-N-hydroksy-benzamid;

5-(3-etoksy-5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-yl)-isoksazol-3-ol;

5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-pyridin-2-yl-tiofen-2-karboksylsyre;

[6-(4-etylamino-tiofen-2-yl)-pyrimidin-4-yl]-[2-(7-fluor-2,4-dimetyl-indol-1-yl)-etyl]-amin;

[6-(4-etylamino-tiofen-2-yl)-pyrimidin-4-yl]-[2-(6-fluor-2,4-dimetyl-indol-1-yl)-etyl]-amin;

[6-(4-etylamino-tiofen-2-yl)-pyrimidin-4-yl]-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-amin;

N-etyl-N-(5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-3-yl)-formamid;

N-(3-etoksy-5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-yl)-formamid;

N-(3-etoksy-5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-yl)-propionamid;

N-(3-etoksy-5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-yl)-3-hydroksy-propionamid;

(3-etoksy-5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-yl)-urea; og

5-{6-[2-(2-cyano-3,7-difluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-trifluormetyl-tiofen-2-karboksylsyre;

eller et farmasøytisk akseptabelt salt derav.

12. Forbindelse ifølge krav 1, valgt fra gruppen som består av:

3-klor-5-{6-[2-(4-klor-7-fluor-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

3-klor-5-{6-[2-(6-fluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

(2-klor-4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenyl)-metanol;

5-{6-[2-(7-fluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-metyl-tiofen-2-karboksylsyre;

[6-(2,3-dihydro-1H-indol-5-yl)-pyrimidin-4-yl]-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-amin;

[2-(6-fluor-2,4-dimetyl-indol-1-yl)-etyl]-{6-[4-(1H-imidazol-4-yl)-fenyl]-pyrimidin-4-yl}-amin;

[2-(4-metoksy-2-metyl-indol-1-yl)-etyl]-{6-[4-(2H-pyrazol-3-yl)-fenyl]-pyrimidin-4-yl}-amin;

{6-[4-(1H-imidazol-4-yl)-fenyl]-pyrimidin-4-yl}-[2-(4-metoksy-2-metyl-indol-1-yl)-etyl]-amin;

[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-[6-(2-metyl-1H-benzoimidazol-5-yl)-pyrimidin-4-yl]-amin;

3-etyl-5-{6-[2-(7-fluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

3-fluor-5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

3-fluor-5-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

(4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-metoksy-fenyl)-metanol;

(2-etoksy-4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenyl)-metanol;

[2-(6,7-difluor-2,4-dimetyl-indol-1-yl)-etyl]-{6-[4-(1H-imidazol-4-yl)-fenyl]-pyrimidin-4-yl}-amin;

5-{6-[2-(4,5-difluor-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

5-{6-[2-(5-klor-7-fluor-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

2-etylamino-4-{6-[2-(6-fluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-benzosyre;

2-etylamino-4-{6-[2-(7-fluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-benzosyre;

2-etylamino-4-{6-[2-(4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-benzosyre;

3-etoksy-5-{6-[2-(4-metoksy-2,7-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

3-etoksy-5-{6-[2-(5,6,7-trifluor-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

[2-(6,7-difluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-[6-(4-[1,2,4]oksadiazol-5-yl-fenyl)-pyrimidin-4-yl]-amin;

[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-{6-[4-(1-metyl-1H-pyrazol-3-yl)-fenyl]-pyrimidin-4-yl}-amin;

3-(4-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenyl)-4H-[1,2,4]oksadiazol-5-on;

4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-propyl-benzosyre;

1-etyl-3-(2-metoksy-4-{6-[2-(4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenyl)-urea;

2-klor-6-etylamino-4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-benzosyre;

[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-(6-kinolin-6-yl-pyrimidin-4-yl)-amin;

2-etylamino-6-fluor-4-{6-[2-(7-fluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-benzosyre;

4-{6-[2-(7-klor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etylamino-benzosyre;

2-klor-4-{6-[2-(6-fluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-6-propyl-benzosyre;

2-klor-4-{6-[2-(7-fluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-6-propyl-benzosyre;

2-fluor-4-{6-[2-(7-fluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-6-propyl-benzosyre;

4-{6-[2-(5,7-difluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-benzosyre;

2-klor-4-{6-[2-(4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-6-propyl-benzosyre;

{6-[4-(2-amino-5-metyl-tiazol-4-yl)-fenyl]-pyrimidin-4-yl}-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-amin;

5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-propyl-2,3-dihydro-isoindol-1-on;

2-syklobutoksy-4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-benzosyre;

4-{6-[2-(2-cyano-6-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-benzosyre;

2-etylamino-6-fluor-4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-benzosyre;

4-{6-[2-(6,7-difluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-benzosyre;

4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-propoksy-benzosyre;

4-{6-[2-(5,7-difluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-isobutyl-benzosyre;

2-klor-4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-6-propyl-benzosyre;

2-fluor-4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-6-propyl-benzosyre;

2-fluor-4-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-6-propyl-benzosyre;

2-butoksy-4-{6-[2-(7-fluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-benzosyre;

4-{6-[2-(7-fluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-isobutoksy-benzosyre;

4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-isobutyl-benzosyre;

2-(4-{6-[2-(7-fluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenyl)-tiazol-4-karboksylsyre;

[2-(6-fluor-2,4-dimetyl-indol-1-yl)-etyl]-{6-[4-(2-metyl-1H-imidazol-4-yl)-fenyl]-pyrimidin-4-yl}-amin;

2-(4-{6-[2-(4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenyl)-tiazol-4-karboksylsyre;

4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-trifluormetyl-benzensulfonamid;

{6-[4-(5-amino-[1,3,4]tiadiazol-2-yl)-fenyl]-pyrimidin-4-yl}-[2-(6-fluor-2,4-dimetyl-indol-1-yl)-etyl]-amin;

[2-(6,7-difluor-2,4-dimetyl-indol-1-yl)-etyl]-{6-[4-(2-metyl-1H-imidazol-4-yl)-fenyl]-pyrimidin-4-yl}-amin;

4-(4-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenyl)-tiazol-2-karboksylsyre;

[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-{6-[4-(5-metyl-1H-pyrazol-3-yl)-fenyl]-pyrimidin-4-yl}-amin;

4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-(2,2,2-trifluor-etylamino)-benzosyre;

2-syklopentyloksy-4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-benzosyre;

2-butoksy-4-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-benzosyre;

4-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-isobutoksy-benzosyre;

4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-isobutoksy-benzosyre;

4-{6-[2-(6,7-difluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-isobutyl-benzosyre;

4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-2-metyl-pyrimidin-4-yl}-2-isobutyl-benzosyre;

2-klor-4-{6-[2-(5,7-difluor-2,4-dimetyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-6-propoksy-benzosyre;

4-{6-[2-(6,7-difluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-fluor-6-propoksy-benzosyre;

4-{6-[2-(6,7-difluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-(2,2,2-trifluor-etylamino)-benzosyre;

[2-(5-klor-7-metyl-[1,3]dioksolo[4,5-e]indol-6-yl)-etyl]-{6-[3-etylamino-4-(1H-tetrazol-5-yl)-fenyl]-pyrimidin-4-yl}-amin;

{6-[3-etoksy-4-(1H-tetrazol-5-yl)-fenyl]-pyrimidin-4-yl}-[2-(7-fluor-2,4-dimetyl-indol-1-yl)-etyl]-amin;

{6-[3-etoksy-4-(1H-tetrazol-5-yl)-fenyl]-pyrimidin-4-yl}-[2-(4-metoksy-2-metyl-indol-1-yl)-etyl]-amin;

3-(4-{6-[2-(6-klor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenyl)-4H-[1,2,4]oksadiazol-5-on;

2-klor-4-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-6-isobutoksy-benzosyre;

[2-(6-fluor-2,4-dimetyl-indol-1-yl)-etyl]-[6-(1H-indol-5-yl)-pyrimidin-4-yl]-amin;

[2-(7-fluor-2,4-dimetyl-indol-1-yl)-etyl]-[6-(1H-indol-5-yl)-pyrimidin-4-yl]-amin;

[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-[6-(1H-indol-5-yl)-pyrimidin-4-yl]-amin;

[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-[6-(1-metyl-1H-indol-5-yl)-pyrimidin-4-yl]-amin;

[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-[6-(1-metyl-1H-indol-5-yl)-pyrimidin-4-yl]-amin;

[2-(6,7-difluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-[6-(1-metyl-1H-indol-5-yl)-pyrimidin-4-yl]-amin;

2-klor-4-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-6-(2,2,2-trifluor-etoksy)-benzosyre;

2-klor-4-{6-[2-(6,7-difluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-6-(2,2,2-trifluor-etoksy)-benzosyre;

2-klor-4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-6-(2,2,2-trifluor-etoksy)-benzosyre;

[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-[6-(4-pyrazin-2-yl-fenyl)-pyrimidin-4-yl]-amin;

6-{6-[2-(7-klor-5-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-1,2-dihydro-indazol-3-on;

3-etoksy-5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-1-metyl-etylamino]-pyrimidin-4-yl}-tiofen-2-karboksylsyre;

5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-hydroksy-tiofen-2-karboksylsyre;

1-(3-etoksy-5-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-tiofen-2-yl)-etanol;

(2-etoksy-4-{6-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenylamino)-eddiksyremetylester;

7-fluor-4-metoksy-1-{2-[6-(2-trifluormetyl-pyridin-4-yl)-pyrimidin-4-ylamino]-etyl}-1H-indol-2-karbonitril;

3-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-5-metoksy-benzosyre;

7-fluor-4-metoksy-1-{2-[6-(2-okso-2,3-dihydro-1H-benzoimidazol-5-yl)-pyrimidin-4-ylamino]-etyl}-1H-indol-2-karbonitril;

4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-N-(2-metoksy-etyl)-benzamid;

7-fluor-1-[2-(6-imidazo[1,2-a]pyridin-6-yl-pyrimidin-4-ylamino)-etyl]-4-metoksy-1H-indol-2-karbonitril;

7-fluor-1-{2-[6-(2-okso-2,3-dihydro-1H-benzo[d]imidazol-5-yl)-pyrimidin-4-ylamino]-etyl}-4-metoksy-1H-indol-2-karbonitril;

1-{2-[6-(2-syklopropyl-pyridin-4-yl)-pyrimidin-4-ylamino]-etyl}-7-fluor-4-metoksy-1H-indol-2-karbonitril;

1-{2-[6-(2-azetidin-1-yl-pyridin-4-yl)-pyrimidin-4-ylamino]-etyl}-7-fluor-4-metoksy-1H-indol-2-karbonitril;

4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-benzosyre;

7-fluor-4-metoksy-1-{2-[6-(2-metyl-3-okso-2,3-dihydro-1H-indazol-6-yl)-pyrimidin-4-ylamino]-etyl}-1H-indol-2-karbonitril;

7-fluor-4-metoksy-1-{2-[6-(3-metoksy-1H-indazol-6-yl)-pyrimidin-4-ylamino]-etyl}-1H-indol-2-karbonitril;

(4-{6-[2-(4-klor-2-cyano-6,7-difluor-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-fenoksy)-eddiksyre;

5-{6-[2-(4-klor-2-cyano-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-fluor-tiofen-2-karboksylsyre;

5-{6-[2-(2-cyano-7-fluor-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-fluor-tiofen-2-karboksylsyre;

(4-{6-[2-(2-cyano-5,6-difluor-4-metyl-indol-1-yl)-etylamino]-pyrimidin-4-y}-2-etoksy-fenylamino)-eddiksyre;

5-{6-[2-(7-klor-5-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

2-butoksy-4-{6-[2-(6-klor-7-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-benzosyre;

5-{6-[2-(4,7-diklor-5-fluor-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-etoksy-tiofen-2-karboksylsyre;

(2-etoksy-4-{6-[2-(6-fluor-4-metoksy-2-metyl-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenylamino)-eddiksyre;

5-{6-[2-(2-cyano-7-fluor-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-trifluormetyl-tiofen-2-karboksylsyre;

5-{6-[2-(4,6-diklor-2-cyano-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-trifluormetyl-tiofen-2-karboksylsyre;

5-{6-[2-(4,6-diklor-2-cyano-indol-1-yl)-etylamino]-pyrimidin-4-yl}-3-fluor-tiofen-2-karboksylsyre;

[6-(3-etoksy-4-oksazol-2-yl-fenyl)-pyrimidin-4-yl]-[2-(7-fluor-4-metoksy-2-metyl-indol-1-yl)-etyl]-amin; og

(2-klor-4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-fenoksy)-eddiksyre;

eller et farmasøytisk akseptabelt salt derav.

13. Forbindelsen ifølge krav 1, som er 4-{6-[2-(2-klor-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-benzosyre eller et farmasøytisk akseptabelt salt derav.

14. Forbindelsen ifølge krav 1, som er 4-{6-[2-(2-cyano-7-fluor-4-metoksy-indol-1-yl)-etylamino]-pyrimidin-4-yl}-2-etoksy-benzosyre eller et farmasøytisk akseptabelt salt derav.

15. Farmasøytisk sammensetning omfattende, som aktivt prinsipp, en forbindelse ifølge et hvilket som helst av kravene 1 til 14, eller et farmasøytisk akseptabelt salt derav, og minst ett terapeutisk inert hjelpestoff.

16. Forbindelse ifølge et hvilket som helst av kravene 1 til 14, eller et farmasøytisk akseptabelt salt derav, for anvendelse som et medikament.

17. Forbindelse ifølge et hvilket som helst av kravene 1 til 14, eller et farmasøytisk akseptabelt salt derav, for anvendelse i forebygging eller behandling av sykdommer valgt fra gruppen som består av kreft; smerte; endometriose; autosomal dominerende polycystisk nyresykdom; akutte iskemiske syndromer hos aterosklerotiske pasienter; lungebetennelse; og nevrodegenerative sykdommer; eller for anvendelse for å kontrollere kvinnelig fruktbarhet.

18. Forbindelse ifølge et hvilket som helst av kravene 1 til 14, eller et farmasøytisk akseptabelt salt derav, for anvendelse i forebygging eller behandling av en kreft valgt fra melanom; lungekreft; blærekreft; nyrekarsinomer; gastrointestinale kreftformer; livmorkreft; eggstokkreft; livmorhalskreft; og nevroblastom.

19. Anvendelse av en forbindelse ifølge et hvilket som helst av kravene 1 til 14, eller et farmasøytisk akseptabelt salt derav, ved fremstilling av et medikament for forebygging eller behandling av sykdommer valgt fra gruppen som består av kreft; smerte; endometriose; autosomal dominerende polycystisk nyresykdom; akutte iskemiske syndromer hos aterosklerotiske pasienter; lungebetennelse; og nevrodegenerative sykdommer; eller for kontroll av kvinnelig fruktbarhet.

20. Forbindelse ifølge et hvilket som helst av kravene 1 til 14, eller et farmasøytisk akseptabelt salt derav, for anvendelse i en fremgangsmåte for å modulere en immunrespons hos et individ som har en svulst; hvori fremgangsmåten reaktiverer immunsystemet i svulsten til individet.